Clinical Protocols

Oncology Division

Oncology Clinical Trials

 

 

Hematology Division

Click on the title of a protocol to view its description in ClinicalTrials.gov.
 

Disease Protocol (Sponsor) Status PI/Contact Comments
TTP/microangiopathy TITAN Phase II Single-Blind Randomized Placebo Controlled Trial to Study Efficacy and Safety of Anti-VWF Nanobody in Patients with Acquired TTP (Ablynx) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Suspected TTP prior to starting PEx
ITP Randomized Trial with Open-Label Extension to Evalulate the Efficacy and Safety of Oral E5501 vs. Eltrombopag in Adults with ITP (Eisai) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Relapsed ITP
Iron overload/MDS TELESTO A Multicenter, Randomized, Double-Blind Placebo Controlled, Clinical Trial of Desferasirox in Patients with MDS (Low/Int-1 risk) and Transfusional Iron Overload (Novartis) Open PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Low/Int-1 MDS Transfusion Dependent
Iron deficiency Distribution of Iron Isotopes 56Fe and 54Fe in the Serum of Iron Deficiency Anemia and Anemia of Chronic Disease Patients (Internal) Open PI: Mitch Scott
Contact: Morey Blinder
mblinder@dom.wustl.edu
Suspected iron deficiency of ACD in pre-menopausal women
Thrombosis ATTRACT (NIH) Open PI: Suresh Vedantham
Contact: Morey Blinder
mblinder@dom.wustl.edu
New DVT
Atypical HUS Registry of patients with atypical HUS Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
Atypical HUS
Banking Laboratory Studies Blood Acquistion for Investigation of Thrombotic Disorders (NIH) Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
Thrombosis Banking
PNH PNH Registry (Alexion) Open PI: Elaine Majerus
Contact: Shatesha Boyce
boyces@wustl.edu
PNH Registry
Hemophilia/Bleeding American Thrombosis and Hemostasis Network Data Collection Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Sickle Cell Disease NKTT Phase 1 Trial of a Monoclonal Antibody Against NK T Cells Open PI: Elaine Majerus Hb SS and S Beta Null
Sickle Cell Disease Phase II Trial of Regadenoson as an Inhibitor of NK T Cells in the Treatment of Sickle Cell Crisis Open PI: Elaine Majerus HbSS and S Beta Null
Chuvash polycythemia Ruxolitinib for Chuvash Polycythemia (WU/Incyte) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Compassionate-use study with ruxolitinib for Chuvash polycythemia
Myelofibrosis A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post- Essential Thrombocythemia Myelofibrosis (Gilead) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
No prior JAKi therapy
Polycythemia Vera or Essential Thrombocythemia A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia (Gilead) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
No prior JAKi therapy
Myelofibrosis A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PERSIST-2) (CTI) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Prior JAKi therapy allowed
Myelofibrosis A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post- polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib (Gilead) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Prior JAKi therapy allowed
Polycythemia Vera Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL) (Incyte) Pending PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
CNL/aCML Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR (Incyte/OHSU) Pending PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
Polycythemia Vera or Essential Thrombocythemia Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (Gilead) Pending PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
TTP/microangiopathy Adjuvant Low Dose Rituximab for Acquired TTP with Severe ADAMTS-13 Deficiency Open PI: Evan Sadler
Contact: Leili Dolatshahi
dolatshahi_l@wustl.edu
Low dose Rituximab for TTP